- Prostate cancer is currently the most frequently diagnosed malignancy among men and the second leading cancer cause of death.
- Approximately 1 in 6 men older than 50 years will be diagnosed with prostate cancer.
Jordan’s Prostate Cancer Program offers a comprehensive diagnostic, counseling and treatment program for male patients at all stages of the disease – which claims the lives of more than 30,000 U.S. men every year.
Our multidisciplinary program includes medical staff with recognized expertise in all major areas of prostate cancer concerns, including: education and counseling, diagnosis, surgery, pathology, radiation (including especially focused external beam x-ray modalities – IMRT), medical oncology, hormone intervention therapy, and now: brachytherapy (seed implantation therapy)
Brachytherapy: An Enhancement of Beth Israel Deaconess - Plymouth’s Prostate Cancer Program:
Brachytherapy is designed for men with a diagnosis of early stage prostate cancer, and has been shown to be an effective treatment for men with localized disease. Patients undergo a minimally invasive procedure where the physician implants tiny permanent radioactive seeds (about the size of a grain of rice) into the prostate, where they irradiate the cancer from inside the gland. The seeds are small enough that they are not felt by the patient.
The addition of this new treatment option allows Jordan’s prostate oncology program to be a comprehensive one, offering the full complement of current therapies for prostate cancer, including surgery, radiation, chemotherapy, hormonal intervention and other treatment therapies.